natgillin/translations-raw huggingface dataset:
Thus, the compounds of the invention are useful for the treatment of allergic asthma, as well as, e.g., exercise induced asthma, occupational asthma, asthma induced following bacterial infection, other non-allergic asthmas and "wheezy-infant syndrome". 
Tako se, dakle, spojevi formula (1) i (1a) mogu upotrijebiti za liječenje alergijske astme, kao također i npr. kod astme uzrokovane poslom, profesionalnu astmu, astme izazvane nakon bakterijske infekcije, različitih ne-alergijskih astmi i sindroma teškog disanja kod djece (e. "wheezy- infant syndrome").
providing at least one candidate sequence, which consist of an amino acid sequence modified by substituting one or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NO: 214, 196, 202, 210, 213, 217 and 223; 
osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78;
the viral antigen is whole killed virus, live attenuated virus or viral purified proteins. 
virusni antigen su cijeli ubijeni virus, živi oslabljeni virus ili pročišćeni virusni proteini.
An antagonistic antibody molecule having specificity for human OX40, which is a modified Fab fragment having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11 and having attached to the cysteine at position 226 of the heavy chain a lysyl-maleimide group wherein each amino group of the lysyl residue has covalently linked to it methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da. 
Protutijelo koje ima specifičnost za ljudski OX40 prema zahtjevu 1, naznačeno time što modificirani Fab ulomak ima teški lanac koji sadrži sekvencu navedenu u SEQ ID NO:15 i laki lanac koji sadrži sekvencu navedenu u SEQ ID NO:11 i koji su vezani na cistein na položaju 226 teškog lanca protutijela lizil-maleimidne skupine; pri čemu svaka amino skupina lizilnog ostatka ima na nju kovalentno vezan metoksipoli(etilenglikol) ostatak koji ima molekulsku masu od oko 20,000 Da.
the rodent wt extracellular domain of FAPa on the cell surface; 
(ili) izvanstaničnu domenu FAPo. glodavca divljeg tipa na površini stanice;
Process according to anyone of the previous claims, wherein the compound of formula (I) is in the form of a salt, in particular hydrochloride salt. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da spoj s formulom (1) je u obliku soli, naročito hidrokloridne soli.
The nitrogen scavenging drug for use as in claim 1 or 4, further comprising a step of determining the upper limit of normal for blood ammonia for the subject. 
Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu prema zahtjevu 1 ili 4, naznačen time da nadalje sadrži korak određivanja gornje granice normale za amonijak u krvi za subjekta.
the C1-4alkoxy or C1-4alkylamino of R1 is unsubstituted or substituted by 1 to 2 substituents independently selected from C1-4alkyl and C1-4alkoxy; and 
-4alkoksi ili C1-4alkilamino od R1, je nesupstituiran ili supstituiran s 1 do 2 supstituenta neovisno odabrana iz niza koji čine C1-4alkil i C1-4alkoksi; i
A process as claimed in claim 5 wherein the acid is acetic acid, 2-chloro-acetic acid, methoxy-acetic acid, propionic acid, butyric acid, valeric acid or pivalic acid or a mixture of at least 2 of aforesaid acids. 
HR P20140248 T1 diazabiciklo[5.4.Olundec-7-en, 7-metil-1,5,7-triazabiciklo[4.4.0]dec-5-en, 1,5,7-triazabiciklo[4.4.0]dec-5-en ili 2-terc-butilimino-2-dietilamino-1,3-dimetilperhidro-1,3,2-diazafosforin; i kiselina je octena kiselina, 2-kloroctena kiselina, metoksioctena kiselina, propionska kiselina, maslačna kiselina, valerijanska kiselina ili pivalinska kiselina, ili smjesa najmanje 2 od navedenih kiselina.
A genetically modified mouse, comprising a humanization of an endogenous mouse IL-6Ra gene, wherein the humanization comprises a replacement of mouse IL-6Ra ectodomain-encoding sequence with human IL-6Ra ectodomain-encoding sequence at the endogenous mouse IL-6Ra locus, and wherein the humanized IL-6Ra gene is under control of endogenous mouse regulatory elements. 
Genetički modificirani miš, koji sadrži humanizaciju endogenog mišjeg IL-6Ra gena, naznačen time da se humanizacija sastoji od zamjene mišje IL-6Ra sekvence koja kodira ektodomenu sa ljudskom IL-6Ra. sekvencom koja kodira ektodomenu na lokusu endogenog miša IL-6Ro, te pri čemu je humanizirani IL-6Ra gen pod kontrolom regulacijskih elemenata endogenog miša.
Method for the construction of continuous vertical diaphragm walls formed of panels that are made with control and adjustment of the verticality of the dig, using a metal joint holder on the shorter side of one of said panels, the dig being made using a hydraulic bucket, with a metal guide on the lateral side of the dig, adjacent to the previously constructed panel, said metal guide being provided on said metal joint holder and following the entire depth of the dig, wherein the verticality is controlled and adjusted during the digging phases using a metal guide characterized in that the metal guide is fitted with a control device that continuously controls the verticality of the dig and another device to adjust said verticality when needed. 
PATENTNI ZAHTJEVI L m Metoda izrade trajnog vertikalnog potpornog zida formiranog od panela kojima se kontrolira i prilagođuje vertikalitet iskopa, korištenjem metalnog zglobnog držača na kraćoj strani rečenog panela, iskop koji je napravljen pomoću hidrauličke košare, sa metalnom vodilicom na bočnoj strani iskopa, usporedno sa prethodno izrađeni panelom, a rečena metalna vodilica je sadržana na metalnom zglobnom držaču po cijeloj dubini iskopa, a vertikalitet iskopa se kontrolira i prilagođuje tijekom cijelog iskopa pomoću metalne vodilice naznačeno time da je metalna vodilica opremljena kontrolnim uređajem koji neprestano kontrolira vertikalitet iskopa i dodatnog uređaja koji prilagođuje vertikalitet po potrebi.
A process for the manufacture of the crystalline form as claimed in claim 1 or claim 6 which comprises prolonged stirring of a solution of an amorphous form of a compound of formula I. 
Postupak za proizvodnju kristaliničnog oblika prema bilo kojem od Zahtjeva 1 do 5, naznačen time da sa sastoji od dugotrajnog miješanja vodene otopine amorfnog oblika spoja prikazanog formulom I (u skladu sa definicijom u Zahtjevu 1).
A marine vessel according to claim 10, wherein the tank body is of elongated form having a longitudinal axis wherein the tank body is arranged into the marine vessel its longitudinal axis at an angle in respect to the longitudinal axis of the vessel around the vertical axis of the vessel. 
Pomorsko plovilo prema zahtjevu 8, naznačeno time da je tijelo spremnika (12) izduženog oblika koje ima uzdužnu os pri čemu je tijelo spremnika (12) smješteno u pomorsko plovilo (100) i njegova uzdužna os je pod kutom u odnosu na uzdužnu os plovila oko okomite osi plovila.
Another embodiment of the present invention is a combination of an M3 antagonist which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide with a PDE4 inhibitor selected from cilomilast, roflumilast, denbufylline, and tetomilast. 
Sljedeće utjelovljenje predmetnog izuma je kombinacija M3 antagonista, koji je spoj 3(R)-(2-hidroksi-2,2-ditien-2- ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo[2.2.2]oktan bromid s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid 1 flutikazon propionat.
it has an improved homogeneity in particular compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line ATCC No. 
- ima poboljšanu homogenost, osobito u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
ET-743 purity evaluation after 6 months storage at 5°C. 
Procjena čistoće ET-743 poslije 6 mjeseci čuvanja na 5*C.
A pharmaceutical formulation according to claim 7 which contains one or more additional active agent(s) in addition to high purity degree safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the respective impurity of formula (IIa) or (IIb) or a salt thereof with a pharmaceutically acceptable acid is lower than 0.03% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 3, naznačena time što sadrži jedno ili više dodatnih aktivnih sredstava uz safinamid ili ralfinamid visoke čistoće, ili njihove soli s farmaceutski prihvatljivom kiselinom, gdje je sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb), ili njihovih soli s farmaceutski prihvatljivom kiselinom, niži od 0,03% (težinski).
The colloidal suspension may be diluted to a colloidal suspension with a concentration of said nano-crystalline powder in the range 0.05 to 5% by weight, such as a 0.1 to 3% by weight, and preferably the concentration of said nano-crystalline powder in said colloidal suspension is in the range 0.3-2 wt % such as 0.4 to 1 wt %. In such concentration levels the colloidal suspension produced according to the present invention is substantially optically clear. 
Postupak prema zahtjevu 1. naznačen time da je volumenski udio navedenih zrnaca za mljevenje (9) u navedenoj komori za mljevenje (4; 4A; 4B; 4C) u rasponu od 60-95 % kao što je 70-90 %, te poželjno daje volumenski udio navedenih zrnaca za mljevenje u navedenom postupku mljevenja u rasponu od 75-85 %, kao što je 80-85 %.
The method according to claim 1, which further comprises at least one chelating agent selected from ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje kompozicija dalje sadrži najmanje jedan helatni agens odabran od etilen diamintetraoctene kiseline (EDTA) 1 etilen glikol tetraoctene kiseline (EGTA).
A process according to claim 13 wherein the polymer shell is selected from the group of polyamides, polyesters, polyurethanes, polyureas. 
Postupak prema zahtjevu 12 naznačen time da je polimerna ovojnica odabrana iz skupine koju čine poliamidi, poliesteri, poliuretani, poliuree.
A compound represented by the formula (I) wherein R1 is a hydrogen atom, a halogen atom or an alkyl group having a carbon number of 1 to 6 optionally having substituent(s); 
Spoj, naznačen time, da je predstavljen formulom (1) gdje R' je atom vodika, atom halogena ili alkilna skupina koja ima broj ugljika od 1 do 6 opcijski sa supstituentima;
The antibody of any one of claims 1-7, which exhibits one or more immune effector functions against a cell carrying CLDN6 in its native conformation, wherein the one or more immune effector functions are preferably selected from the group consisting of complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), induction of apoptosis, and inhibition of proliferation, preferably the effector functions are ADCC and/or CDC. 
Antitijelo suglasno bilo kojem od zahtjeva 1-7, koje pokazuje jednu ili više imunskih efektorskih funkcija usmjerenih prema stanicama koje pokazuju CLDN6 u njegovoj nativnoj formi, naznačeno time da je jedna ili više efektorskih funkcija poželjno izabrana iz grupe koji čine citotoksičnost zavisna od komplementa (CDC), citotoksičnost posredovana antitijelima (ADCC), indukcija apoptoze i inhibicija proliferacije, a poželjno je da su efektorske funkcije ADCC i/ili CDC.
The residue was chromatographed on silica gel (50% ethyl acetate:cyclohexane) to give the title compound (0.26 g, 21%) as a yellow oil which was a mixture of diastereoisomers. 
Ostatak se kromatografira na silikagelu (50 % etil-acetat/cikloheksan) kako bi se dobilo naslovni spoj (0,26 g, 21 %) u obliku žutog ulja, koje je smjesa dijastereoizomera.
The magnesia cement of any one of claims 1 to 8, characterized in that the caustic magnesia component consists of caustic magnesia obtained by calcination of magnesium compounds at a temperature below 1100 °C, preferably of caustic magnesia obtained by calcination of magnesium compounds at a temperature of between 750 °C and 900 °C, wherein said magnesium compounds are fine powders before calcination and have an average particle size of less than 45 µm, preferably of 1 - 40 µm, and/or a BET specific surface area of greater than 0.4 m2/g. 
Magnezijski cement prema bilo kojem od zahtjeva 1 do 8, naznačen time što sastojak kaustične magnezije se sastoji od kaustične magnezije dobivene kalcinacijom magnezijevih spojeva na temperaturi ispod 1100°C, poželjno od kaustične magnezije dobivene kalcinacijom magnezijevih spojeva na temperaturi između 750°C i 900°C, pri čemu su spomenuti magnezijevi spojevi fini prašci prije kalcinacije i imaju prosječnu veličinu čestice manju od 45 µm, poželjno od 1 - 40 µm, i/ili BET specifičnu površinu veću od 0,4 m2/g.
The method according to claim 1, wherein, in the compound of Formula I, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, R2 is H. 
2. < Spoj sukladno patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv kokristal, stereoizomer, mješavina stereoizomera ili tautomer, naznačeno time što R? je H.
A solution of compound 6f (0.1 g, 0.19-mmol) and succinic semialdehyde (15 wt % solution in water; 0.13 mL, 0.21 mmol) in MeCN was stirred at room temperature for 5 minutes. 
Otopinu spoja 6f (0,1 g, 0,19 mmol) i sukcinsemialdehida (15 %, težinski, otopina u vodi; 0,13 ml, 0,21 mmol) u MeCN se miješa 5 minuta na sobnoj temperaturi.
The antibody according to any of claims 1 to 7 for use according to claim 13, wherein the second agent is a chemotherapeutic agent. 
Farmaceutski sastav, naznačen time, da sadrži protutijelo prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prihvatljiv nosač.
The undesirable side effects associated with antipsychotic or antidepressant agents include weight gain, somnolence and cognitive impairment. 
Nepoželjne nuspojave povezane s antipsihotičikm ili antidepresivnim agensima uključuju dobitak na težini, somnolenciju i kognitivni poremećaj.
The compound of claim 1, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof. 
: ili njegova farmaceutski prihvatljiva sol. 4. Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
A pharmaceutical composition comprising as an active agent a cell of claims 1 or 16, optionally together with pharmaceutically acceptable diluents, carriers and adjuvants. The composition of claim 23, which is a living vaccine suitable for administration to a mucosal surface or via the parenteral route. A method for the preparation of a living vaccine comprising formulating a cell of claims 1 or 16 in a pharmaceutical effective amount with pharmaceutically acceptable diluents, carriers and adjuvants. 
Farmaceutska smjesa, naznačena time što kao djelatnu tvar obuhvaća stanicu prema zahtjevu 1 ili 16, po izboru zajedno s farmaceutski prihvtaljivim punilima, nosačima i pomoćnim tvarima, Smjesa prema zahtjevu 23, naznačena time što je to živo cjepivo prikladno za primjenu na površine sluznica ili parenteralnim putem, . Postupak pripreme živog cjepiva, naznačen time što obuhvaća oblikovanje stanice, prema zahtjevu 1 ili 16, u farmaceutski učinkovitu količinu, s farmaceutski prihvtaljivim punilima, nosačima i pomoćnim tvarima,
Then a further 100µl PBS was added to each plate and then, without prolonged incubation, removed using a plate washer. 
Potom se opet pločice kratko isperu sa 100 ul PBS, kojeg se nakon kratke inkubacije ukloni pomoću ispirača mikrotitarskih pločica.
Use of the bispecific antibody or antibody fragment of any one of the claims 1 to 7 in research or in vitro diagnostic applications, wherein said bispecific antibody or antibody fragment thereof comprises a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela 12 bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
Utilities and Combinations 
Korist i kombinacije
The leveling spacer according to claim 1, wherein said base has four equidistant spacing protrusions and is designed to be arranged below four converging corners of a corresponding number of tiles. 
Umetak za niveliranje prema prethodnim zahtjevima, naznačen time, da spomenuta osnova (11) ima četiri jednako udaljene izbočine za razmak (12, 12a, 12b, 126) 1 konstruirana je za raspoređivanje ispod četiri konvergentna ugla od odgovarajućeg broja pločica.
The seasonal thermal energy storage system for cold and heat supply of claim 8, characterized in that temperature sensors and liquid level detectors are disposed in the heat source storage pond, the cold source storage pond, the hot water supply pool, and the cold water supply pool; and all the water pumps are provided with a magnetic valve. The seasonal thermal energy storage system for cold and heat supply of claim 9, characterized in that the system further comprises an intelligent control unit, the intelligent control unit is connected to the temperature sensors, the liquid level detectors, and the magnetic valve for controlling the opening/closing of the magnetic valve according to signals gathered by the temperature sensors and the liquid level detectors whereby opening/closing corresponding water pumps. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 4, naznačen time što su temperaturni senzori i detektori razine tekućine smješteni u bazenu za pohranjivanje izvora topline (11), bazenu za pohranjivanje rashladnog izvora (12), bazenu za opskrbu toplom vodom (41), te bazenu za opskrbu hladnom vodom (42); sve vodene crpke imaju magnetski ventil; inteligentna upravljačka jedinica spojena je na temperaturne senzore, detektore razine tekućine, te magnetski ventil za kontrolu otvaranja/zatvaranja magnetskog ventila prema signalima koje prikupljaju temperaturni senzori 1 detektori razine tekućine pri čemu se otvaraju/zatvaraju odgovarajuće vodene crpke.
applying the aerated mixture to an agricultural crop. 
(c) nanošenja aerirane smjese na poljoprivredni usjev.
ml vanilla extract. 
4 ml ekstrakta vanilije
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivno plućne bolesti.
Number of clones and library diversity 
Broj međunarodne prijave:
A further embodiment of the present invention provides the dihydrogenphosphate salt drug substance of structural formulae I-III that comprises the crystalline monohydrate present in a detectable amount. 
Daljna implementacija predmetnog izuma daje dihidrogenfosfatnu sol supstance lijeka strukturne formule I-III koja sadržava kristalni monohidrat nazočan u detektabilnoj količini.
contacting the pre-incubated sample with HPVLPs immobilized on a solid substrate under conditions suitable for binding of a JCV antibody in the sample to an HPVLP; 
(b) stavljanju u kontakt predinkubiranog uzorka s HPVLP-ima, koji se pretežno sastoje od proteina VP1 iz JCV, imobiliziranih na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP;
The device of claim 1, wherein the adhesive is a mixture of an organic solvent and polymer glue, wherein an amount of organic solvent used is sufficient to allow the polymer glue to be mixed. 
Uređaj prema zahtjevu 1, naznačen time da je ljepilo smjesa organskog otapala i polimernog ljepila, pri čemu je korištena količina organskog otapala dovoljna da omogući miješanje polimernog ljepila.
The latching system of claim 1, wherein the post further comprises a stem (622) disposed proximal to the groove, wherein the stem and the distal end of the second angular edge each have a greater maximum lateral thickness than the groove. 
Sustav za bravljenje u skladu s patentnim zahtjevom 1, naznačen time što potporanj dodatno sadrži držak (622) smješten u blizini žlijeba, gdje svaki od drška 1 udaljenog kraja drugog ruba kuta ima veću maksimalnu bočnu debljinu nego žlijeb.
A powdery composition comprising a steroidal molecule; and a pharmaceutically acceptable carrier having a specific surface area of 200-1000 m2/g; wherein the steroidal molecule is dissolved in a solvent absorbed onto the surface of the pharmaceutically acceptable carrier and wherein the steroidal molecule is present in the solvent in a supersaturated concentration. 
PATENTNI ZAHTJEVI Praškasti kompozit, naznačen time, da sadrži steroidnu molekulu; i amorfni silicijev dioksid koji ima specifičnu površinu od najmanje 250 m'/g; gdje je steroidna molekula otopljena u otapalu apsorbiranom na površinu amorfnog silicijevog dioksida i gdje je steroidna molekula prisutna u otapalu u superzasičenoj koncentraciji.
The device according to claim 1, further including a permanent magnet dynamo (69) and in that said float (5, 50) is sized to provide at least the required torque to said dynamo at a rate of 10rpm. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da sadrži trajni dinamo magnet (69), te da je navedeni plovak (5,50) takve veličine da osigurava barem zahtijevani moment iz navedenog dinama pri brzini od 10 okretaja u minuti.
The compound for use of claim 10, wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate. 
Spoj za upotrebu prema patentnom zahtjevu 10, naznačen time što je farmaceutski prihvatljiva sol izabrana iz grupe koja se sastoji od acetata, askorbata, benzoata, benzensulfonata, bisulfata, borata, butirata, citrata, kamforata, kamforsulfonata, fumarata, hidroklorida, hidrobromida, hidrojodida, laktata, maleata, metansulfonata, naftalensulfonata, nitrata, oksalata, fosfata, propionata, salicilata, sukcinata, sulfata, tartarata, tiocijanata i toluensulfonata.
A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: 
Derivat fenilpirazola prikazan formulom (1) ili njegova farmaceutski prihvatljiva sol: 1
A pharmaceutical composition according to claim 10 wherein the composition is lyophilised. 
Farmaceutski sastav u skladu s patentnim zahtjevima 10 ili 11 pri čemu je sastav liofiliziran.
A pharmaceutical composition comprising the antibody of any one of claims 1-7, or an antigen binding fragment thereof, the nucleic acid of claim 8 or 9, the vector of claim 10, or the cell of claim 11, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1-7, ili njegov ulomak koji veže antigen, nukleinsku kiselinu prema zahtjevu 8 ili 9, vektor prema zahtjevu 10, ili stanicu prema zahtjevu 11, te farmaceutski prihvatljivo sredstvo za razrjeđivanje 1li nosač.